Trials / Completed
CompletedNCT03764462
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-101 in healthy volunteers
Detailed description
This study is to evaluate the pharmacokinetic characteristics and safety of AD-101 compared with administration of raloxifen 60 mg in healthy adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-101 45mg | Raloxifene 45mg tablet |
| DRUG | Raloxifene 60mg | Raloxifene 60mg tablet |
Timeline
- Start date
- 2018-12-14
- Primary completion
- 2019-01-02
- Completion
- 2019-02-08
- First posted
- 2018-12-05
- Last updated
- 2019-08-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03764462. Inclusion in this directory is not an endorsement.